Last updated: March 2026
Benfotiamine (S-benzoylthiamine O-monophosphate) is a synthetic fat-soluble derivative of thiamine with dramatically higher bioavailability than standard vitamin B1. Clinical trials demonstrate benefits for diabetic neuropathy, AGE (advanced glycation end-product) reduction, and early-stage Alzheimer's cognitive decline.
Benfotiamine is a synthetic S-acyl derivative of thiamine (vitamin B1). Unlike water-soluble thiamine HCl, benfotiamine is lipid-soluble — it passively diffuses across intestinal membranes rather than relying on saturable active transport, resulting in dramatically higher blood and tissue thiamine levels.
Benfotiamine activates transketolase, which shunts excess glucose metabolites into the pentose phosphate pathway — away from AGE (advanced glycation end-product) formation. AGEs are toxic protein modifications linked to diabetic complications, neurodegeneration, and aging. In the Alzheimer's trial (Gibson et al. 2020, PMID: 33074237), benfotiamine significantly reduced blood AGE levels (p = 0.044).
Transketolase is the thiamine diphosphate (ThDP)-dependent enzyme at the heart of the pentose phosphate pathway. Benfotiamine raises intracellular ThDP levels far more effectively than regular thiamine, supercharging this enzyme. Hammes et al. (2003, PMID: 12606524) showed benfotiamine blocked three of the four major pathways of hyperglycemic damage in diabetic animal models via this mechanism.
In transgenic Alzheimer's mouse models, benfotiamine reduced amyloid-β plaques, decreased phosphorylated tau, and improved cognitive performance (Pan et al. 2010, PMID: 20413890). Tapias et al. (2018, PMID: 29788461) showed benfotiamine activated the Nrf2/ARE antioxidant pathway and was neuroprotective in a tauopathy model. The human Phase IIa trial showed 77% less clinical worsening on the CDR scale (p = 0.034).
Benfotiamine modulates NF-κB signaling, arachidonic acid inflammation pathways, and protein kinase B cascades. It prevents macrophage death from lipopolysaccharide challenge and inhibits monocyte adhesion to endothelial cells. In activated microglia, it inhibits inflammatory mediators and enhances anti-inflammatory factor production — relevant to both diabetic complications and neurodegeneration.
Water-soluble thiamine (B1) has a hard absorption ceiling — the intestinal transporter saturates at relatively low doses. Fat-soluble derivatives bypass this bottleneck entirely.
Key study: Xie et al. (2014, PMID: 24399744) measured plasma thiamine bioavailability of benfotiamine at 1,147% ± 490% relative to thiamine HCl — roughly an 11× improvement. Erythrocyte TDP (the active coenzyme form) was 196% of thiamine HCl. Earlier work by Bitsch et al. (1991, PMID: 1776825) reported approximately 5× greater bioavailability in a 10-subject crossover study.
Important nuance: Benfotiamine is the champion for raising blood and peripheral tissue thiamine levels. However, unlike sulbutiamine and TTFD, benfotiamine may not cross the blood-brain barrier as effectively. Its central effects in the Alzheimer's trial may work through peripheral AGE reduction and anti-inflammatory mechanisms rather than direct CNS thiamine delivery.
Data from published human clinical trials on benfotiamine across neuropathy, diabetes, and neurodegeneration.
Note on evidence quality: Benfotiamine has real human trial data — including a 12-month randomized placebo-controlled Alzheimer's trial and the BENDIP neuropathy RCT. Most trials are small-to-moderate in size. The evidence is promising but requires larger confirmatory studies.
Benfotiamine is one of the few supplements with an actual randomized placebo-controlled trial specifically for Alzheimer's disease. Here are the key studies.
600mg/day benfotiamine in MCI/mild AD patients. CDR worsening reduced 77% (p = 0.034), ADAS-Cog decline reduced 43% (p = 0.125, not significant), AGE reduced (p = 0.044), FDG-PET improved (p = 0.002). Safe and well-tolerated over 12 months. Phase IIb trial (BenfoTeam) is planned.
In Alzheimer's transgenic mice (APP/PS1), benfotiamine reduced amyloid-β plaque numbers, decreased phosphorylated tau levels, elevated phosphorylation of GSK-3α/β, and improved memory performance. Provided the preclinical basis for the human trial.
In a transgenic tauopathy model, benfotiamine activated the Nrf2/ARE antioxidant defense pathway, reduced tangle formation, and improved behavioral deficits. Demonstrates a direct neuroprotective mechanism beyond simple AGE reduction.
165 patients with diabetic polyneuropathy randomized to benfotiamine 300mg/day, 600mg/day, or placebo. NSS (Neuropathy Symptom Score) significantly improved at 600mg in per-protocol population (p = 0.033). Improvement was dose-dependent and increased with treatment duration. TSS (Total Symptom Score) showed no significant difference at 6 weeks.
Benfotiamine dosing from published clinical trials and common supplementation protocols. Always start low and assess tolerance.
Benfotiamine works within the B-vitamin metabolic network. These cofactors support its mechanisms and prevent downstream bottlenecks:
Benfotiamine has an excellent safety record across clinical trials. As a B-vitamin derivative, excess is generally excreted rather than accumulated.
An honest assessment of the benfotiamine research as of 2026.
Benfotiamine supplements and companion products for B1 optimization.
Affiliate links help support MeetPeptide at no extra cost to you.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and informational purposes only. It is not medical advice. Benfotiamine is sold as a dietary supplement in the United States. It is not an FDA-approved drug for any condition. The clinical trials cited on this page are preliminary and do not constitute proof of efficacy for treating, curing, or preventing any disease. Always consult a qualified healthcare provider before starting any supplement regimen, especially if you have diabetes, neuropathy, or cognitive concerns. Individual responses vary significantly. MeetPeptide does not provide medical advice or sell supplements.